Autonomix Medical, Inc. announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detect real-time changes in neural activity following intervention. The platform is expected to target expansion into the multi-billion-dollar cardiovascular market with a potential Class II diagnostic regulatory path. The architecture supports future expansion into denervation, including renal, pulmonary, cardiac, splanchnic, and other nerve-targeted applications, with potential compatibility across multiple denervating technologies.

The standalone neural sensing platform will be built on the same core sensing technology as Autonomix's lead pancreatic cancer pain program and is being developed in parallel with that initiative. This enables a capital-efficient expansion into cardiology, which represents a significant new therapeutic market opportunity. In recent preclinical studies, changes in blood pressure were induced and reproducible changes were observed in recorded neural signals in real time.

Additional studies are underway to further characterize the relationship between these signals and sympathetic nerve activity. These findings highlight the potential for a more precise, feedback-driven or closed-loop approach to renal denervation. This may address a longstanding challenge in the field, where the absence of direct physiological feedback can contribute to variability in treatment outcomes.

Renal denervation has emerged as a promising treatment option for patients with uncontrolled or resistant hypertension and represents a large and growing market. Autonomix believes that incorporating neural sensing into the procedure, which would enable physicians to identify active nerve targets, guide therapy delivery, and confirm treatment effect in real time, may offer meaningful differentiation in this space with improved procedural consistency, precision, and efficacy.

While Autonomix’s initial focus for the standalone neural sensing platform will be renal denervation, the underlying architecture is designed to be indication-agnostic and is applicable wherever autonomic nerve activity drives disease. The Company believes this positions the platform for future expansion into pulmonary nerve applications, ganglionated plexi for atrial fibrillation, splanchnic nerve therapies, and other indications where precise nerve detection and procedural confirmation could meaningfully improve outcomes.

"These preclinical results support what we believe is a fundamental advantage of our platform – to see the nerve, guide the therapy, and confirm the result in real time," said Brad Hauser, Chief Executive Officer of Autonomix. "The standalone platform strategy opens a capital-efficient path into cardiology and beyond, and a potentially more focused development and regulatory pathway."

Autonomix intends to pursue additional preclinical studies and evaluate further expansion in a staged manner that builds on the regulatory and clinical foundation established through renal denervation. Autonomix’s sensing technology has been presented at leading interventional cardiovascular scientific forums, including Transcatheter Cardiovascular Therapeutics, Cardiovascular Research Technologies, and EuroPCR. Autonomix was recently recognized with one of CRT 2026’s Best Cardiovascular Innovation Awards.

Autonomix Medical, Inc. announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21 reverse stock split of its common stock. The reverse split will take effect at 12:01 am (Eastern Time) on June 24, 2026. Trading on The Nasdaq Capital Market will commence on a post-split basis the same day under the existing ticker symbol "AMIX" but with a new CUSIP number 05330T304.

As a result of the reverse stock split, every 21 shares of the Company's common stock issued and outstanding prior to the opening of trading on June 24, 2026 will be consolidated into one issued and outstanding share. The nominal par value per share of $0.001 remains unchanged. No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment in lieu of that share.

Share Structure Impact

The reverse split significantly reduces the number of shares outstanding. The total authorized shares of common stock remain unchanged at 500 million shares. Additionally, the number of shares reserved for issuance under the Company's equity compensation plan will be reduced proportionately.

Autonomix is a medical device company focused on advancing technologies to revolutionize the diagnosis and treatment of diseases involving the nervous system. The Company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals. The technology is currently investigational and has not yet been cleared for marketing in the United States.